Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for COVID-19
NCT04348071Phase 3Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ruxolitinib in coronavirus disease 2019 (COVID-19), sponsored by University of Colorado Denver. Planned start Jul 2021; status: withdrawn.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04348071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348071.